Regarding safety outcomes, SGLT2 inhibitors do not seem to increase the risk of hypoglycemia, while a previous meta -analysis demonstrated that, when added to metformin, SGLT -2 inhibitors are associated with the lowest odds for hypoglycemia, compared with the remaining second -line oral antidiabetic agents. 5 Of course, extra caution is needed as far as the risk of diabetic ketoacidosis and lower extremity amputation is concerned. 2 An appropriate adjustment of the remaining antidiabetic regimen may be needed.
Overall, the insulin -independent mechanism of action and the multilevel pleiotropic effects of SGLT2 inhibitors make them an attractive treatment option in the elderly population. Oral once--daily administration and availability of fixed combinations with metformin might also be considered as an advantage. However, this hypothesis needs to be tested in large prospective clinical trials with SGLT2 inhibitors, enrolling exclusively the geriatric population. A closer look at the baseline characteristics of patients reveals that this study included elderly obese patients with type 2 diabetes and significant comorbidities, mainly arterial hypertension (up to 89.0%), macrovascular disease (up to 32.4%), and advanced chronic kidney disease (up to 31.1%). Patients were stratified according to glycemic control, depending on glycated hemoglobin A 1c levels (tight, moderate, and poor control). Minimal differences between the 3 study groups were detected.
1
It is certain that, at the time of this study, sodium -glucose co -transporter 2 (SGLT2) inhibitors were still considered as novel drugs, with limited preliminary data concerning their efficacy and safety. However, it is now established (based on data obtained from the 3 hallmark cardiovascular outcome trials, namely, the EMPA--REG OUTCOME [ Recent evidence also highlights their superiority compared with dipeptidyl peptidase-4 inhibitors, in terms of cardiovascular morbidity or mortality and all -cause mortality.
3 In addition, they exert only a modest effect on glycemic control of patients with type 2 diabetes and concomitant chronic kidney disease, with a mean reduction in glycated hemoglobin levels up to 0.29%; thus, they do not correlate with "intensification" of glycemic control.
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